Navigation Links
Hope builds for a drug that might shut down a variety of cancers
Date:11/7/2013

NEW YORK (November 7, 2013) -- The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53. Targeting these enzymes with novel agents might prevent the growth of p53 mutant cancers, thereby benefiting a broad spectrum of cancer patients, including those with breast, ovarian, lung, colorectal and brain tumors.

In the Nov. 7 issue of Cell, investigators pinpoint two cellular enzymes -- Type 2 phosphatidylinositol-5-phosphate 4-kinases α and β (Type 2 PIP kinases) -- as essential for cancer growth when cells have lost p53, the powerful tumor-suppressor gene long dubbed the "guardian of the genome." More than half of all cancers lose this gene, allowing these cancers to grow at will.

The researchers discovered that the Type 2 PIP kinases are not critical for the growth of normal cells but become essential for cell growth when p53 is lost due to mutations or deletions. The scientists showed, in animal and lab studies of human cancer cells, that targeting these molecules effectively shuts down the growth of p53 mutant cancers.

Although the studies were conducted in human breast cancer cells, the researchers believe Type 2 PIP kinase inhibitors could block the growth of cancers with a mutated or missing p53 gene.

"The fact that one can delete the Type 2 PIP kinases in normal human cells or in mice with essentially no effect on cell survival suggests that inhibitors of these enzymes should have little toxicity," says Dr. Cantley, the study's senior author and director of the Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.

Dr. Cantley is already leading an effort to develop drugs to shut down these kinases. "Well-designed Type 2 PIP kinase inhibitors may turn the tide on p53 mutant cancer," he says.

A Crucial Link

Dr. Cantley is known for his discovery of the PI 3-kinase oncogene, and pioneering work in teasing apart how the gene contributes to cancer. PI 3-kinases (PI3K) have been linked to a wide variety of cellular functions, including cell growth and proliferation, and most cancers activate PI3K by one or more mechanisms. Dr. Cantley's discovery led to promising avenues for the development of personalized cancer therapies.

Activity of PI3K is in some cases linked to Type 2 PIP kinases, so in this study, Dr. Cantley sought to understand the function of these enzymes. Because the researchers knew that a subset of breast cancers over-express these molecules, investigators looked at their role in HER2-positive breast cancers, which typically are more aggressive tumors.

The researchers, including those from Harvard Medical School, Beth Israel Deaconess Medical Center and other institutions, discovered that the enzymes are silent in cells that have healthy p53. One critical role of p53 is to "rescue" cells that are producing excess reactive oxygen species (ROS), which are byproducts of cells that are growing too rapidly. The oxidative stress produced by ROS can damage cell structures, so p53 attempts to reduce ROS in affected cells. "If, however, ROS levels exceed the capacity of p53s to rescue it, then p53 takes on a second function, which is to kill the cell," Dr. Cantley says.

"That is why cancers often disable p53. If p53 is mutated or gone, then the cell keeps on growing at a very high rate," he says. "And then ROS begins to damage genes, making the cancer even more aggressive."

The Type 2 PIP kinases are the backup rescue system to p53. But they only reduce ROS enough to keep the cells from dying. (Too much ROS will also kill a cell.)

What this means is that cancer cells become "absolutely dependent on these kinases to be able to grow," Dr. Cantley says.

Taking Advantage of "Synthetic Lethality"

But there is a big and important hitch in this scenario, he adds. If the Type 2 PIP kinases are inhibited, and if p53 is deactivated, the cancer cell essentially "goes to sleep," he says. "It just stops dividing and growing. This is called synthetic lethality: You can get by without one gene or another, but if you lose both of them nothing can grow."

Shutting down these enzymes, as the researchers did in their experiments, puts cancer cells to sleep but has no effect on healthy cells. "A normal cell doesn't need Type 2 PIP kinases at all, so inhibitors of these enzymes should not be toxic to humans," Dr. Cantley says.

Because it is not possible to replace p53 proteins or the gene in cells that have lost it (many attempts have been made), deactivating Type 2 PIP kinases is the next-best thing, he adds. "This would likely be a very powerful advance in the treatment of many cancers."


'/>"/>

Contact: Sarah Smith
sas2072@med.cornell.edu
646-317-7401
Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Unique Dry Eye Relief Technology Builds Momentum with a New Global Patent
2. Under Tiger Woods' Feet? Colton Powell, a Master of Turf Management, Works the Colonial and Preps for Augusta as Western Texas College Builds a Pipeline to PGA Tour
3. Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee
4. Elliance Webinar Explores How Responsive Web Design for Magazines Builds Readership in the Age of Mobile Media
5. Study shows confidence builds better exercise habits for cancer survivors
6. Momentum builds in quest to find cure for childhood brain disease
7. Novel surgery removes rare tumor, rebuilds face and jaw
8. As Heat Builds, Take Steps to Protect Yourself
9. MicroRNA-31 might predict lung-cancer spread
10. Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
11. Extended primary care office hours might help keep kids out of the emergency department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... ... June 13, 2019 , ... MMJ BioPharma Cultivation, a ... a memorandum of understanding (MOU) with MMJ International Holdings to grow cannabis and ... MMJ BioPharma Cultivation will be supplying MMJIH with extracts from the marijuana plant ...
(Date:6/13/2019)... ... 2019 , ... Charm Sciences, Inc. is pleased to announce ... the 2019 National Conference of Interstate Milk Shipments for screening milk tankers according ... test was validated by third party laboratories working in collaboration with the AOAC ...
(Date:6/13/2019)... SAN DIEGO (PRWEB) , ... June 13, 2019 ... ... 96-hour pain relief patch, announces their partnership with cannabis delivery company, Driven Deliveries, ... , Driven Deliveries, Inc., covers 93% of the population of California with ...
(Date:6/13/2019)... Va. (PRWEB) , ... June 13, 2019 , ... ... awards programs, is proud to present the second annual Women|Future Conference ... that will allow attendees to better position themselves and their organizations in tomorrow's ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... to everyone in healthcare, today announced that Jon Elwell, the company’s CEO, has ... DirectTrust™. DirectTrust is a non-profit health care industry alliance created to ...
Breaking Medicine News(10 mins):
(Date:6/16/2019)... ... ... AVIE! MedSpa and Laser Center is proud to offer Vivace™ Fractional Micro ... dramatic improvements to the texture and tightness of skin on any area of the ... needles, spurring vibrant new collagen growth for a wide range of complexion improvements, including ...
(Date:6/16/2019)... (PRWEB) , ... June 15, 2019 , ... ... afflicts 1.4% of the global population. The condition is characterized by damage ... medical complications including thyroid disease, anemia, osteoporosis, fertility problems and some cancers, to ...
(Date:6/14/2019)... Fla. (PRWEB) , ... June 14, 2019 , ... ... pleased to announce the release of their new website designed to help patients obtain ... health innovations. , Land O’ Lakes, Florida Chiropractor, Dr. Michael Craven is ...
Breaking Medicine Technology: